Cargando…
Baseline Characteristics and Secondary Medication Adherence Patterns Among Patients Receiving Tafamidis Prescriptions: A Retrospective Analysis Using a National Specialty Pharmacy Dispensing Database
INTRODUCTION: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a serious, underrecognized condition, which leads to heart failure and early mortality if left untreated. Until recently, heart transplantation was the only treatment for ATTR-CM. Regulatory approval of tafamidis transformed treatment f...
Autores principales: | Roy, Anuja, Peterson, Andrew, Marchant, Nick, Alvir, Jose, Bhambri, Rahul, Lynn, Jason, Benjumea, Darrin, Prasad, Sapna, O’Brien, Alex, Chen, Yong, Kemner, Jason, Parasuraman, Bhash |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9064174/ https://www.ncbi.nlm.nih.gov/pubmed/35517043 http://dx.doi.org/10.2147/PPA.S352332 |
Ejemplares similares
-
Baseline characteristics and secondary medication adherence among Medicare patients diagnosed with transthyretin amyloid cardiomyopathy and/or receiving tafamidis prescriptions: A retrospective analysis of a Medicare cohort
por: Roy, Anuja, et al.
Publicado: (2022) -
Real-World Characteristics of Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy: An Analysis of Electronic Healthcare Records in the United States
por: Bhambri, Rahul, et al.
Publicado: (2023) -
Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial
por: Li, Benjamin, et al.
Publicado: (2020) -
Tafamidis and tafamidis meglumine for amyloid cardiomyopathy
Publicado: (2021) -
Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy
por: Rozenbaum, Mark H., et al.
Publicado: (2022)